“Global Anti-Obesity Drugs market set to grow to $6.3bn by 2023” says new Visiongain report
20 November 2018
Visiongain has launched a new pharma report: Global Anti-obesity Drugs Market Report : Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs
The Global Anti-Obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MoA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.
The lead analyst of the report commented "During the forecast period, the global market is driven by the raising prevalence of overweight and obesity population; increasing awareness about the disease; growing diagnosis & treatment rates; obesity being recognized as a disease, adoption of national and international level policies by various countries.
In the global market, challenges continue with huge healthcare budget constraints, weak late-stage promising pipeline, generic competition, unavailability of safer & effective treatments, and availability of alternate therapies."
Leading companies featured in the report include Eisai/Arena, GlaxoSmithKline (GSK), Novo Nordisk, Orexigen/Takeda, Roche, Teva, Vivus
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Recent News
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Read
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
Read
Visiongain Publishes Single-use Bioprocessing Probes & Sensors Market Report 2023-2033
The global Single-Use Bioprocessing Probes & Sensors market was valued US$2,493.8 million in 2022 and is projected to grow at a CAGR of 15.2% during the forecast period 2023-2033.
22 May 2023
Read
Visiongain Publishes Dental Consumables Market Report 2023-2033
The global Dental Consumables market is valued at US$21,759.4 million in 2023 and is expected to register a CAGR of 8% from 2023 to 2033.